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Abstract
 
Interferon (IFN)-
 
g
 
–induced cells express the proteasome subunits low molecular weight protein
(LMP)2, LMP7, and MECL-1 (multicatalytic endopeptidase complex–like 1), leading to the for-
mation of immunoproteasomes. Although these subunits are thought to optimize MHC class I
antigen processing, the extent of their role and the mechanistic aspects involved remain unclear.
Herein, we study the proteolytic generation of an human histocompatibility leukocyte antigen
(HLA)-Aw68–restricted hepatitis B virus core antigen (HBcAg) cytotoxic T lymphocyte (CTL)
epitope that is recognized by peripheral blood lymphocytes from patients with acute self-limited
but not chronic hepatitis B virus (HBV). Immunological data suggest that IFN-
 
g
 
–induced rather
than uninduced HeLa cells process and present the HBV CTL epitope upon infection with
HBcAg-expressing vaccinia viruses. Analyses of 20S proteasome digests of synthetic polypeptides
covering the antigenic HBcAg peptide demonstrate that only immunoproteasomes efficiently per-
form the cleavages needed for the liberation of this HBV CTL epitope. Although the con-
certed presence of the three immunosubunits appears essential, we find that both catalytically ac-
tive LMP7 and inactive LMP7 T1A support CTL epitope generation. We conclude that LMP7
influences the structural features of 20S proteasomes, thereby enhancing the activity of the LMP2
and MECL-1 catalytic sites, which provide cleavage specificity. Thus, LMP7 incorporation is of
greater functional importance for the generation of an HBV CTL epitope than cleavage specificity.
Key words: antigen processing • LMP7 T1A • hepatitis B virus • immunoproteasome • MHC 
class I
 
Introduction
 
The MHC class I Ag processing pathway allows CTLs to
survey the inner cellular protein contents. Cytosolic en-
dogenous and foreign proteins are degraded into peptides
that bind the TAP (transporter associated with Ag process-
ing) and are translocated into the endoplasmic reticulum.
Peptides containing an appropriate motif are bound by
newly synthesized MHC class I molecules, which then
travel to the cell surface (for review see reference 1).
Proteasomes, the major cytosolic proteinase complexes,
are essential for the generation of most MHC class I–pre-
sented peptides. Indeed, treatment of cells with membrane-
permeable proteasome inhibitors inhibits cytosolic Ag deg-
radation, production of antigenic peptides, and, due to a
shortage of peptides in the endoplasmic reticulum, mark-
edly impairs MHC class I assembly and cell surface trans-
port (2–6). Proteasomes consist of a 20S catalytic core that
is built from 28 (14 different) subunits, arranged as four
heptameric rings (for review see reference 7). The two
outer rings contain the structural alpha subunits (
 
a
 
1–
 
a
 
7);
the inner rings contain 
 
b
 
 subunits (
 
b
 
1–
 
b
 
7), of which three
(
 
b
 
1, 
 
b
 
2, and 
 
b
 
5) exert catalytic activity. Binding of 20S
proteasomes to 19S regulatory complexes (PA700) confers
protein degrading capacity and substrate specificity, includ-
ing that for ubiquitin-conjugated proteins.
Stimulation of cells with IFN-
 
g
 
 induces the expression
of the proteasome activator PA28
 
ab
 
 and three additional
catalytic proteasome subunits, e.g., the subunits low molec-
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ular weight protein (LMP)2
 
1
 
 and LMP7, encoded in the
MHC class II region, and MECL-1 (multicatalytic endo-
peptidase complex–like 1; for review see references 8 and 9).
These subunits replace the constitutive subunits delta (
 
b
 
1),
MB1 (
 
b
 
5), and MC14 (mouse) or Z (human) (
 
b
 
2) in newly
formed so-called immunoproteasomes. Although the asso-
ciation with PA28 has been shown to promote the produc-
tion of MHC class I binding peptides, most likely by in-
creasing the rate of dual cleavages by 20S proteasomes (10,
11), the role of the IFN-
 
g
 
–induced catalytic subunits is still
unclear. In vitro studies using fluorogenic tri- and tetrapep-
tides as substrates have shown that the incorporation of im-
munosubunits alters the catalytic activity of 20S proteasomes
(12–16). However, the physiological relevance of the ef-
fected changes is unclear.
Surprisingly, accurate results were obtained with polypep-
tides as substrates to document proteasomal cleavage site
preferences. Several studies have shown that 20S protea-
somes liberate MHC class I ligands out of larger polypep-
tides or denatured proteins in vitro (13, 17) with rates that
correlate well with those of production of the antigenic
peptide in intact cells (18–21). This became especially clear
in a study examining the generation of an immunodomi-
nant CTL epitope from the murine (m)CMV pp89 protein
(18). Flanking of the pp89 antigenic peptide with alanine
residues resulted in enhanced cleavage out of a pp89
polypeptide, both if synthetic polypeptide was degraded by
purified proteasomes and if polypeptide-encoding sequences
were expressed from a minigene in intact cells. Further-
more, the presence of preferred proteasomal cleavage sites
was found to prevent efficient MHC class I presentation of
OVA and of a murine leukemia virus CTL epitope (19,
20), whereas a point mutation destroying a specific cleav-
age site in the p53 protein inhibited CTL epitope genera-
tion (21). Remarkably, whereas digestion with purified pro-
teasomes in either substrate studied generated the exact
COOH terminus of MHC class I binding peptides, the
NH
 
2
 
-terminal cleavage was not always as precise. Thus, as
also indicated by other studies (22), additional nonproteaso-
mal proteases may trim the NH
 
2
 
 terminus of antigenic pep-
tides in intact cells.
The influence of proteasome composition on antigenic
peptide generation was studied for the pp89 substrate (14,
23). It was found that the association of the LMP subunits
with the proteasome changed cleavage specificity, resulting
in the generation of a qualitatively and quantitatively differ-
ent set of peptides. However, an obvious effect on the gen-
eration of the pp89 antigenic peptide was not observed
(8, 10, 14). In other studies using cell lines lacking the LMPs,
the production of certain viral CTL epitopes appeared di-
minished, whereas the presentation of other epitopes was
not influenced (24–27). Furthermore, LMP2 and LMP7
knockout mice showed partial deficits in MHC class I Ag
 
presentation (28, 29). Thus, these data indicate that immu-
noproteasomes contribute to MHC class I Ag processing,
but the extent of their role is presently unclear.
The question arises of how the IFN-
 
g
 
–inducible sub-
units affect MHC class I Ag processing. The simultaneous
expression of both constitutive and inducible subunits in
IFN-
 
g
 
–stimulated cells could, by enhancing the choices for
active site subunits, simply function to increase the hetero-
geneity of the cytosolic proteasome population (30). As-
suming that each subunit adds its own unique cleavage
specificity to the proteasome, this would enhance the like-
lihood that antigenic peptides would be generated. Alter-
natively, the association of the IFN-
 
g
 
–inducible subunits
may in a more specific way alter the cleavage properties of
proteasomes, such as to enhance the generation of ligands
suitable for binding to MHC class I molecules.
To test above hypotheses, we digested a synthetic 32-
mer polypeptide from the hepatitis B virus (HBV) core Ag
(HBcAg) with purified proteasomes and analyzed the pro-
teolytic generation of a contained CTL epitope, HBcAg141-
151, first described by Missale et al. (31). This peptide binds
the MHC class I HLA-A31 and HLA-Aw68 molecules and
is recognized by CD8
 
1 
 
CTLs from patients with acute self-
limited or convalescent HBV (reference 31 and our results).
Our studies show that only immunoproteasomes liberate the
antigenic peptide efficiently. Although the association of
the immunosubunits with the proteasome is essential, we
find that antigenic peptide production also occurs in the
presence of a mutated, catalytically inactive form of one of
the LMPs and thus does not require the full enzymatic ac-
tivity of proteasomes. We conclude that structural changes
induced by the incorporation of, in particular, LMP7 influ-
ence the proteasome-mediated cleavages, resulting in an
enhanced production of MHC class I–presentable peptides.
 
Materials and Methods
 
Cell Lines.
 
C4 (BALB/c) mouse fibroblast cells (14) were cul-
tured in Iscove’s MEM (Biochrom), and the human cervical carci-
noma cell line HeLa, the human lymphoblastoid cell line T2 (32),
and T2 transfectant cell lines were cultured in RPMI (Biochrom).
All media were supplemented with 10% FCS, 2 mM 
 
l
 
-glutamine,
penicillin (100 U/ml), and streptomycin (100 
 
m
 
g/ml). Stimulation
with 20 U/ml of murine (C4 cells) or human (HeLa cells) recombi-
nant (r)IFN-
 
g
 
 (Boehringer Mannheim) was performed for 72 h be-
fore harvesting. T2 transfectant lines expressing the mouse protea-
some subunits LMP2, LMP7, mutant LMP2 T1A, or mutant LMP7
T1A and combinations thereof have been described (23, 33, 34, and
Schmidt, M., and P.-M. Kloetzel, manuscript in preparation).
 
Recovery of HBVcAg141-151–specific PBLs and CTL Assays.
 
PBMCs of a HLA-Aw68
 
1
 
 patient who had recovered from acute
HBV (hepatitis B core [HBc] antibody–positive, hepatitis B sur-
face [HBs] antibody–positive, hepatitis B envelope [HBe] anti-
body–positive, HBeAg-negative, HBsAg-negative) were resus-
pended in RPMI 1640 supplemented with 
 
l
 
-glutamine, penicillin,
streptomycin, and 10% heat-inactivated human AB serum and
stimulated in 96-well round-bottomed plates at 0.2 
 
3
 
 10
 
6
 
 cells
per well with 10 
 
m
 
g/ml synthetic peptide, 10 ng/ml of rIL-7, and
10 pg/ml of rIL-12 (PeproTech Inc.). 20 U/ml of rIL-2 (Chiron
 
1
 
Abbreviations used in this paper:
 
 DCPs, double cleavage products; HBcAg,
hepatitis B virus core antigen; HBV, hepatitis B virus; LMP, low molecu-
lar weight protein; MECL, multicatalytic endopeptidase complex–like; r,
recombinant; SCPs, single cleavage products. 
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Corp.) was added every 3–4 d. The cultures were restimulated
with 10 
 
m
 
g/ml of peptide, 20 U/ml of rIL-2, and 10
 
5
 
 irradiated
(3,000 rads) autologous PBMCs in the presence of rIL-7 on day 7
and in the absence of IL-7 on day 14. A standard CTL assay with
peptide-pulsed autologous PHA blasts was performed on days
20–24 as described previously (35). Alternatively, HeLa cells cul-
tured for 2 d in the absence or presence of 20 U/ml of IFN-
 
g
 
were infected with recombinant vaccinia viruses expressing HB-
cAg (C-Vac; provided by Dr. B. Moss, National Institute of Al-
lergy and Infectious Diseases, National Institutes of Health) and
HBxAg, respectively (X-Vac; provided by Dr. H. Schaller,
ZMBH, Heidelberg, Germany) at a multiplicity of infection of
10 and used as target cells in the CTL assay the next day.
 
Proteasome Isolations.
 
20S proteasomes were purified as de-
scribed (14, 33). The purity of the preparates was checked by Coo-
massie-stained SDS-PAGE and was 
 
.
 
90%. Aliquots were frozen at
 
2
 
80
 
8
 
C until use.
 
Two-dimensional Gel Analysis.
 
Purified proteasomes were
analyzed by nonequilibrium pH gradient gel electrophoresis
(NEPHGE)–SDS-PAGE and Coomassie staining as described (14).
 
Western Blot Analysis.
 
Purified proteasomes were quantified
according to Bradford et al. (36), and samples of 150 ng (for the
detection of LMP7) and 500 ng (for the detection of LMP2)
were separated on 15% SDS–polyacrylamide gels. Immunoblots
were probed with mouse LMP2– and mouse LMP7–specific
polyclonal rabbit antisera as described (37).
 
Peptides.
 
The synthetic 32-mer polypeptide AYRPPNAPIL-
STLPETTVVRRRGRSPRRRTPS derived from HBV (subtype
ayw) cAg, amino acids 131–162, and the 11-mer peptide STL-
PETTVVRR (HBcAg141-151) were provided by Dr. P. Henk-
lein at our institute in Berlin.
 
Peptide Digestion Assays.
 
20 
 
m
 
g of HBV 32-mer polypeptide
and 3 
 
m
 
g of purified proteasomes was incubated in 300 
 
m
 
l of assay
buffer (20 mM Hepes/KOH, pH 7.8, 2 mM MgAc
 
2
 
, 1 mM dithio-
threitol) at 37
 
8
 
C for the time periods specified in the figure leg-
ends and then frozen at 
 
2
 
20
 
8
 
C. 20 
 
m
 
l of digests was separated by
reverse-phase (RP)-HPLC (SMART system equipped with a
 
m
 
RPC C2/C18 SC 2.1/10 column, Pharmacia; eluent A, 0.05%
TFA; eluent B, 70% acetonitrile containing 0.045% TFA; gradi-
ent: 5–63% eluent B in 30 min, 63–95% eluent B in 4 min; flow
rate: 50 
 
m
 
l/min). Analysis was performed on line by a tandem
quadrupol mass spectrometer equipped with an electrospray ion
source (TSQ 7000; Finnigan MAT). Each scan was acquired over
the range m/z 
 
5 
 
300–1,300 in 3 s. The peptides were identified
by their molecular masses calculated from the m/z peaks of the
single or multiple charged ions.
 
Results
 
IFN-
 
g
 
 Treatment Induces Production of HBcAg141-151
CTL Epitopes in Infected Cells.
 
We previously demonstrated
that LMP2 and LMP7 alter the proteasomal cleavage site
preference in a 25-mer peptide from the mCMV pp89
protein (14, 23). To further analyze the impact of the IFN-
 
g
 
–inducible 
 
b
 
 subunits on Ag cleavage and antigenic pep-
tide production, we selected a CTL epitope from the HBV
core Ag, HBcAg141-151, originally identified by Missale
et al. (31). Using peptide variants covering the HBcAg140-
155 region, this group showed that the HBcAg141-151
11-mer represents the sequence optimally recognized by
HLA-A31– and HLA-Aw68–restricted CTLs from a pa-
tient with acute self-limited hepatitis B (31). We now dem-
onstrate that this epitope is also recognized by an HLA-
Aw68
 
1
 
 patient who has clinically and serologically recovered
from HBV infection (Fig. 1 A). HBcAg141-151–specific
CTLs, expanded from PBMCs during 2 wk of in vitro cul-
ture, efficiently lysed autologous HBcAg141-151–coated
PHA blasts with high specific cytotoxicity even at a low
E/T ratio (Fig. 1 A). Thus, HBcAg141-151 is an HBV
epitope that induces MHC class I–restricted CTLs during
acute HBV infection that then persist in the peripheral
blood even after recovery from hepatitis B.
To analyze the effect of immunosubunit expression on
HBcAg141-151 generation, untreated HeLa cells lacking
the immunosubunits and IFN-
 
g
 
–treated HeLa cells were
infected with recombinant vaccinia virus encoding HBcAg
(C-Vac) or with X-Vac virus as a control and then tested
for recognition by HBcAg141-151–specific CTLs (Fig. 1 B).
Whereas untreated C-Vac–infected cells were not recog-
nized, the lysis percentages obtained with IFN-
 
g
 
–treated,
C-Vac–infected HeLa cells exceeded the background lysis
levels of X-Vac–infected induced cells. Thus, only IFN-
 
g
 
–
treated HeLa cells process HBcAg efficiently into HBcAg141-
151 CTL epitopes.
 
Generation of HBcAg141-151 Requires the Presence of Im-
munoproteasomes.
 
To study the proteolytic generation of
HBcAg141-151, proteasomes were purified from mouse
C4 fibroblast cells and human HeLa cells, in which the ex-
pression levels of immunosubunits are low under normal
conditions but highly inducible by IFN-
 
g
 
 (13, 38). A syn-
thetic 32-mer polypeptide corresponding to HBcAg131-
162 (Table I) was incubated with purified proteasomes from
untreated and IFN-
 
g
 
–treated C4 and HeLa cells (Fig. 2)
Figure 1. HBcAg141-151 is processed naturally in IFN-g–induced
HeLa cells. PBMCs of an HLA-Aw681 patient who had recovered from
acute HBV infection were stimulated with 10 mg/ml of synthetic
HBcAg141-151 as described in Materials and Methods. Cytotoxicity of
3-wk cultures was tested in a 4-h 51Cr-release assay against autologous
PHA blasts loaded overnight with synthetic HBcAg141-151 or left un-
loaded (A) or against uninduced or IFN-g–induced HeLa cells infected
with C-Vac or X-Vac recombinant vaccinia virus as described in Materi-
als and Methods (B). Mean percentages of specific lysis of triplicate wells
(y-axis) for different E/T ratios (x-axis) are plotted. 
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and with proteasomes from T2/mouse LMP2
 
1
 
7 transfec-
tant cells (see below). The digestion products were sepa-
rated by RP-HPLC and on-line analyzed with a mass spec-
trometer. In each sample, 
 
.
 
25 peptide products were
detected, from which 13 were generated by two cleavages
(Fig. 3). The digestion products containing either the cor-
rect COOH terminus or the correct NH
 
2 
 
terminus of the
antigenic HBV peptide are depicted in Table I. No detect-
able amounts of the HBV 32-mer were found in any of the
digests, indicating that substrate turnover was complete. As
judged from the HPLC 214-nm UV profiles (not shown),
peptide Ala131–Leu140 was the predominant product in-
dependent of the type of proteasome used, identifying the
Leu140-Ser141 bond, immediately NH
 
2
 
-terminal of the
CTL epitope, as a preferred cleavage site. Strikingly, de-
spite effective and correct usage of the NH
 
2
 
-terminal cleav-
age site of the epitope in the 32-mer polypeptide substrate,
the correct COOH-terminal cleavage resulting in the gener-
ation of HBcAg141-151 only took place in the presence of
proteasomes from IFN-
 
g
 
–treated cells and from LMP2
 
1
 
7
T2 transfectant cells (Table I). In these digests, double cleav-
age products (DCPs) included the peptides Ser141–Val149,
Ser141–Arg150, Ser141–Arg151, and Ser141–Arg152 (Ta-
ble I). In contrast, constitutive proteasomes from untreated
cells produced only the DCPs Ser141–Val149 and Ser141–
Arg152 in detectable amounts and thus failed to generate
the HBV CTL epitope. Our analyses did not reveal the
presence of peptide products containing the correct epitope
COOH terminus but elongated at the NH
 
2
 
 terminus, rep-
resenting potential epitope precursors (Fig. 3).
To examine whether the absence of Ser141–Arg151 in
digests by constitutive proteasomes is caused by lack of
generation or by further degradation, we compared the ki-
netics of product generation upon digestion of the 32-mer
with constitutive proteasomes of T2 cells (see below) and
immunoproteasomes of T2 LMP2
 
1
 
7 cells (Fig. 4). Although
both types of proteasomes preferentially cleaved the Leu140–
Ser141 bond (not shown), immunoproteasomes used this
cleavage site most effectively, resulting in a rapid accumula-
tion of Ser141–Ser162 single cleavage products (SCPs; Fig.
4
 
 
 
A), which at later time points of digestion (8–24 h) were
further degraded into DCPs, including the Ser141–Arg151
CTL epitope (Fig. 4 B). Importantly, the early accumula-
tion of Ser141–Arg151, as quickly as within the first hours
of digestion (Fig. 4 B), suggests that this DCP is also liber-
ated by two simultaneous cuts and is thus not dependent on
the Ser141–Ser162 processing intermediate for its genera-
tion. In contrast, T2 proteasomes cleaved the Leu140–Ser141
 
Table I.
 
Relative Quantities of Peptide Fragments Generated by Digestion of HBcAg131-162 with Purified 20S Proteasomes
 
Peptide fragment
Analysis 1 Analysis 2
 
*
 
C4
 
‡
 
C4
 
1
 
IFN-
 
g
 
HeLa T2 LMP2
 
1
 
7 HeLa
 
1
 
IFN-
 
g
 
T2 LMP2
 
1
 
7
Ala131–Ser162 0
 
§
 
00 0 0 0
Ala131–Leu140 1,201 1,629 578 1,299 2,865 3,851
Ser141–Ser162 14 0 0 0 12 13
Ser141–Val149 151 243 111 194 584 705
Ser141–Arg150 26 214 17 140 444 460
 
Ser141–Arg151 35 201 0 149 478 436
 
Ser141–Arg152 190 260 59 152 794 413
 
*
 
Values shown for analysis 2 were measured in an independent mass spectrometer run and therefore differ quantitatively from the numbers obtained
in analysis 1. For comparison, the peptide digestion products of T2 LMP2
 
1
 
7 proteasomes were analyzed in both runs.
 
‡
 
6.7 
 
m
 
g of HBV 32-mer polypeptide was incubated with 1 
 
m
 
g of 20S proteasome from uninduced or IFN-
 
g
 
–induced C4 or HeLa cells or from T2
LMP2
 
1
 
7 cells for 24 h at 37°C. Cleavage products were analyzed as described in Materials and Methods. The antigenic peptide HBcAg141-151 is
depicted in bold type. No quantitative data for peptide Thr142–Arg151 were obtained.
 
§
 
Measured ion currents 31/1,000. Note that these numbers allow comparison of relative levels of individual but not of different peptides. The mass
spectrometry data were confirmed upon reanalysis of the same digests, and similar data were obtained in several independent digestion experiments.
Figure 2. Subunit composition of 20S proteasomes purified from unin-
duced (A and B) and IFN-g–induced (C and D) mouse C4 and human HeLa
cells. Cells were cultured in the absence or presence of 20 U/ml of mouse or
human rIFN-g for 72 h and then harvested. 20S proteasomes were purified as
described in Materials and Methods, and 50-mg aliquots were subjected to
two-dimensional NEPHGE/PAGE. Separated proteins were stained with
Coomassie blue. Proteasome subunits were assigned on the basis of their mi-
grational behavior (reference 54). The identity of the human LMP7 subunit,
which runs differently from its mouse equivalent, was verified by microse-
quencing (our unpublished observations).507 Sijts et al.
bond at a relatively slow but constant rate over the whole
course of digestion, as evident from a continuous accumu-
lation of the Ala131–Leu140 product (not shown). Re-
markably, the amounts of Ser141–Ser162 SCPs also contin-
ued to increase over the 24 h of digestion (Fig. 4 A), indicating
a poor further degradation into DCPs. Only barely detect-
able amounts of Ser141–Arg151 were generated (Fig. 4 B),
even at later time points of digestion, dismissing Arg151 as
an important cleavage site for constitutive proteasomes.
Taken together, we conclude from this data that the associa-
tion of LMP2, LMP7, and MECL-1 with proteasomes
changes the cleavage site specificity and enhances the fre-
quency of cleavages, leading to efficient production of
HBcAg141-151 CTL epitopes.
Interestingly, the quality and relative quantities of pep-
tides yielded by digestion with proteasomes from untreated
mouse C4 and human HeLa cells or with proteasomes
from IFN-g–treated mouse C4 and human HeLa and hu-
man T2 cells expressing the mouse LMP2 and LMP7 pro-
teins were markedly similar (Table I and data not shown).
Thus, our results do not support the idea of species-specific
proteasomal cleavage properties.
Establishment of a Panel of Proteasomes with Varying Subunit
Composition. To study the contribution of individual cat-
alytic sites to antigenic peptide generation, we took advan-
tage of a panel of T2 transfectant cells that had been gener-
ated in our laboratory. T2 cells lack the endogenous
expression of LMP2 and LMP7, whereas MECL-1 is ex-
pressed but not incorporated into the 20S proteasome due
to the absence of LMP2 (37). Proteasomes were isolated
from parental T2 cells and from T2 cells transfected with
mouse-derived cDNAs encoding LMP2, a mutated, cata-
lytically inactive form of LMP2 (LMP2 T1A), mouse LMP7,
LMP217, or LMP2 plus catalytically inactive LMP7 T1A.
Incorporation of the introduced LMPs was verified by im-
munoblot analyses using specific rabbit antisera (Fig. 5). As
shown in Fig. 5 A, LMP2 was detected as a 21-kD product
in proteasome preparations from LMP2, LMP217, and
LMP217 T1A transfectant cells and as a product with slower
migration properties in proteasomes from LMP2 T1A trans-
fectant cells. The lower electrophoretic mobility of the
T1A mutant forms of LMP2 and LMP7 is due to incom-
plete processing of the NH2-terminal prosequence, which
is an autocatalytic process (33). Likewise, LMP7 (Fig. 5 B)
was detected as a 23-kD protein in purified proteasomes
from LMP7 and LMP217 transfectant cells and as a 26-kD
product in proteasomes from LMP217 T1A transfectant
cells. The exact ratios between constitutive and introduced
b subunits in the used T2 proteasome populations have been
published recently (34) or have been submitted for publi-
cation (Schmidt, M., and P.-M. Kloetzel, manuscript in
preparation) and are of minor importance for the interpre-
tation of our results. In summary, all transfected subunits
replaced their homologous constitutive subunits with .50%
efficiency, with the exception of LMP7 T1A. The incor-
poration of this subunit could not be quantified due to its
unknown migrational behavior in two-dimensional gels
but was less efficient than that of LMP7 as judged from im-
munoblots (Fig. 5 and data not shown). Consistent with
our earlier observations (34, 39), we found that the associa-
tion of both LMP2 and LMP2 T1A with the proteasome
complex induced the simultaneous incorporation of MECL-1
with equal efficiency. Thus, taken together, the isolated set
of proteasomes contained the immunosubunits LMP2 or
LMP2 T1A, each in combination with MECL-1 and with
or without LMP7 or LMP7 T1A.
Efficient HBcAg141-151 Generation Requires the Structural
Information of LMP7. We next examined how the indi-
vidual catalytic sites contribute to the efficient generation
of HBcAg141-151 by immunoproteasomes. The HBV 32-
Figure 3. Peptide fragments detected after digestion of HBcAg131-162
with purified 20S proteasomes. The amino acid sequence of HBcAg131-
162 containing the antigenic epitope HBcAg141-151 is shown in single-
letter code. This 32-mer polypeptide was incubated with 20S proteasome
for 24 h at 378C. Cleavage products were identified by mass spectrometry
after HPLC separation as described in Materials and Methods and are in-
dicated by bars.
Figure 4. Time-dependent generation of a
potential precursor peptide HBcAg141-162 and
of HBcAg141-151. HBcAg131-162 was di-
gested for 0.5, 1, 2, 4, 8, and 24 h with 20S pro-
teasome isolated from T2 cells and T2 LMP217
transfectant cells. Cleavage products were sepa-
rated by HPLC as described in Materials and
Methods but analyzed on-line by an ion trap
mass spectrometer (ThermoQuest) equipped
with an electrospray ion source, which results in
increased sensitivity. Time course of the poten-
tial precursor peptide HBcAg141-162, which is
generated by a single cleavage after Leu140 (A),
and of the antigenic HBcAg141-151 (B) is de-
picted. Plotted values were confirmed by re-
peated analysis of the same digests.508 MHC Class I Antigen Processing by Immunoproteasomes
mer was digested with proteasomes from the different T2
transfectant cells, and the cleavage products were analyzed
(Table II). In agreement with the data shown in Table I
and Fig. 4, we found that in the absence of IFN-g–induc-
ible subunits, as in proteasomes from T2 cells, HBcAg141-
151 was not generated. Remarkably, already the presence
of either LMP2 in combination with MECL-1 or LMP7
alone was sufficient to induce the production of small
amounts of antigenic peptide. In the case of LMP2-con-
taining proteasomes, MECL-1 was most likely not respon-
sible for the observed effect. No antigenic peptide was gen-
erated by digestion with proteasomes containing catalytically
inactive LMP2 T1A and MECL-1. Remarkably, the com-
bined presence of LMP2, LMP7, and MECL-1 resulted in
a significantly more efficient generation of HBcAg141-151
than observed with either of the subunits present alone.
These findings were highly consistent among different ex-
periments (Tables I and II, Fig. 4, Fig. 6) and reproducible
upon repeated mass spectrometric analysis of the same di-
gests or of new digests generated with the same or newly
prepared proteasomes of other T2 clones obtained from the
same transfections (not shown).
Our results argue that the concerted function of immu-
nosubunits is essential for the generation of the HBcAg141-
151 peptide. Strikingly, proteasomes containing a mutated
inactive LMP7 (LMP7 T1A) in addition to wild-type
LMP2 and MECL-1 still generated the HBV CTL epitope
with similar efficiency as in the presence of wild-type LMP7
(Table II). We therefore conclude that the physical pres-
ence of the LMP7 protein in combination with the other
two immunosubunits already contributes to an efficient an-
tigenic peptide production and that the activity of the
LMP7 hydrolytic site is of minor importance.
Kinetic Analysis of Proteasome-mediated Turnover of HBV
Polypeptide. To analyze the importance of LMP7 for ki-
netics and relative abundance of peptide fragments gener-
ated, we performed time course experiments using pro-
teasomes from T2 LMP217 and T2 LMP217 T1A
transfectants. As shown in Fig. 6, the relative abundance of
any of the peptide fragments analyzed was largely similar in
the two proteasomal digests. Whereas the 32-mer substrate
disappeared within the 24 h of digestion, the SCP Ala131–
Leu140 accumulated with reciprocal kinetics. The amount
of SCP Ser141–Ser162 increased at early time points but
then stabilized or slightly diminished, indicating its further
cleavage into the smaller peptides Ser141–Val149, Ser141–
Arg150, the CTL epitope Ser141–Arg151, and Ser141–
Arg152. Peptide fragment Ala131–Arg151, also a potential
precursor of the HBV CTL epitope Ser141–Arg151, con-
tinued to accumulate over the whole period of digestion,
indicating that this SCP was rather resistant to further
cleavage behind Leu140 and was not a major source of an-
tigenic peptide. Thus, whereas LMP2 and MECL-1 pro-
vide the required cleavage site specificity (e.g., ability to
cleave after Arg 151), the incorporation of LMP7 in LMP2/
Figure 5. Incorporation of the
LMP2 and LMP7 subunits in 20S
proteasomes of T2 transfectant lines.
500 ng (A) or 150 ng (B) of purified
20S proteasomes was separated by
SDS-PAGE and probed with mouse
LMP2–specific (A) or mouse
LMP7–specific (B) polyclonal rabbit
antisera. Molecular mass markers
(kD) are shown at left.
Table II. Impact of IFN-g–inducible Proteasome Subunits on the Generation of HBcAg141-151
Peptide fragment T2* T2 LMP2 T2 LMP2 T1A T2 LMP7 T2 LMP217 T2 LMP217 T1A Mock
Ala131–Ser162 0‡ 27 499 0 0 0 1,629
Ala131–Leu140 885 1,299 287 1,540 2,330 2,667 0
Ser141–Ser162 22 27 12 49 6 43 0
Ser141–Val149 66 169 0 42 270 157 0
Ser141–Arg150 0 0 0 67 259 239 0
Ser141–Arg151 0 24 0 68 183 245 0
Ser141–Arg152 69 62 0 180 305 227 0
Thr142–Arg151 60 117 0 0 172 185 0
Pro138–Val149§ 497 503 593 329 265 504 0
*The HBV 32-mer polypeptide was digested with 20S proteasomes purified from T2 and T2 transfectant cells, and digestion products were ana-
lyzed as described in Table I. The antigenic peptide HBc141-151 is depicted in bold type.
‡Measured ion currents 31/1,000. Data were reproduced in at least two independent analyses.
§Ion current data for this and for other peptides not included in this table demonstrate that all purified 20S proteasomes were capable of generating
DCPs.509 Sijts et al.
MECL-1–containing proteasomes changes the frequencies
of cleavage site usage such to support the production of an-
tigenic peptides out of the HBV polypeptide. As the activ-
ity of the LMP7 catalytic site is not required for the ob-
served effect, we assume that the altered cleavage properties
depend on LMP7-induced structural changes in the 20S
proteasome complex.
Discussion
The efficiency and specificity of proteasome-mediated
cytosolic Ag degradation largely shape the pool of peptides
available for binding to MHC class I molecules. Here, we
show that only by incorporating the IFN-g–inducible cata-
lytic subunits proteasomes gain the ability to liberate an
HBcAg CTL epitope from a 32-mer polypeptide.
We used a panel of T2 LMP2/7 transfectant cells to ana-
lyze the impact of individual proteasomal catalytic sites on
peptide cleavage under conditions that bypass other effects
of IFN-g. Whereas the isolated incorporation of LMP2/
MECL-1 and LMP7 had only minor effects on the genera-
tion of the antigenic peptide, the concerted presence of
LMP2, MECL-1, and LMP7 dramatically enhanced the
production of the relevant peptides. This change in the
quality of peptides generated is not simply explained by an
additive effect of cleavages mediated by the catalytic sites of
these subunits; instead, our results suggest that the immuno-
subunits must cooperate in the generation of the HBV
CTL epitope.
Remarkably, although the presence of the LMP7 sub-
unit is essential, the LMP7-restricted proteolytic activity is
apparently not required for effective epitope generation.
Even in the absence of a catalytically active LMP7 subunit
(LMP7 T1A), the generation of HBcAg141-151 is enhanced
(Table II). It should be noted that the efficiency of replace-
ment of especially the constitutive subunit MB1 for LMP7
or LMP7 T1A differed among our proteasome preparates
(Fig. 5 and data not shown). However, as constitutive or
LMP21MECL-1–containing proteasomes generate none or
only low quantities of HBcAg141-151, the proteasome
populations containing either LMP7 or LMP7 T1A must
be responsible for the efficient production of the antigenic
peptide. As the LMP7 capacity to cleave is not essential for
the generation of the HBV CTL epitope, we infer that
structural changes imposed by the incorporation of this im-
munosubunit determine the altered cleavage pattern of im-
munoproteasomes. Efficient generation of HBcAg141-151
further requires the cleavage specificities of the LMP2 and
MECL-1 active site subunits, as the presence of the consti-
tutive subunits in these positions results in a relatively poor
antigenic peptide liberation (compare T2 LMP7 and T2
LMP2[/MECL-1]17 in Table II).
This unexpected finding that structural features besides
functional specificities determine the cleavage properties of
proteasomes finds support from other studies. For example,
we recently reported that the replacement of subunit delta
in constitutive proteasomes by either LMP2 or LMP2 T1A
likewise influences the catalytic activity of the two other
pairs of catalytic sites (39). The groups of Heinemeyer et al.
(40) and Dick et al. (41) recently demonstrated specific ac-
tivities for the individual catalytic subunits using yeast mu-
tant proteasomes. Interestingly, whereas b1 was found re-
sponsible for cleavage after acidic residues and after branched
chain amino acids and b2 for cleavage after basic residues,
cleavages after hydrophobic residues appeared to be exerted
by each of the catalytic subunits (b1, b2, and b5). These
cleavage site preferences, initially documented for short
peptide substrates, also applied for a protein substrate (42).
Likewise, we were able to assign the proteasomal peptidyl
glutamyl hydrolyzing activity (cleavage after acidic residues)
to d (b1) and trypsin-like activity (cleavage after basic resi-
dues) to MC14 (b2) in mammalian proteasomes (33, 43).
Figure 6. Kinetic analysis of the production of HBcAg141-151 and of
related peptide fragments. HBcAg131-162 was digested for 4, 8, or 24 h
with 20S proteasomes isolated from T2 LMP217 (A) and T2 LMP217
T1A transfectant cells (B) or mock-digested (C). Cleavage products were
analyzed as described in Materials and Methods. Relative abundances of
11 selected peptides are plotted. Shown data were reproduced in a sec-
ond, independent experiment.510 MHC Class I Antigen Processing by Immunoproteasomes
However, our preliminary data also show that the genera-
tion, for example, of HBcAg fragments containing arginine
at the COOH terminus occurs less efficiently but is not ab-
rogated in the absence of the MC14/MECL-1 catalytic site
after the incorporation of MECL-1 T1A. Therefore, we
infer that the individual catalytic sites of mammalian pro-
teasomes have overlapping specificities and that so far un-
known structural features appear to tune their activity to an
important extent.
Remarkably, the replacement of MB1 by the transfec-
tion of LMP7 T1A into T2 LMP2 cells resulted in a growth
disadvantage (Schmidt, M., and P.-M. Kloetzel, manuscript
in preparation). Thus, although LMP7 T1A– and LMP7-
containing proteasomes similarly cleave the HBV polypep-
tide studied here, the inactivity of the catalytic site or the
presence of an only partially cleaved prosequence interferes
with the function of proteasomes in intact cells.
Cellular substrates are specifically targeted for proteolysis
by 26S proteasomes, for example by linkage to ubiquitin.
Captured substrates are unfolded by the 19S component
and subsequently degraded by the 20S proteasome. The
process of proteolysis may be modulated by PA28 bound to
the opposite site of 20S (44). To avoid the complexity of
26S proteasome isolations and in vitro substrate targeting,
we and other groups classically use purified 20S proteasomes
and polypeptides as model substrates to study proteolytic
peptide generation. This experimental approach is believed to
accurately document cleavage specificities of cellular protea-
somes, as demonstrated by the comparison of peptide prod-
ucts generated in vitro and in intact cells (18–21). Moreover,
in vitro degradation of denatured OVA protein (17) and of
OVA polypeptides (19) by 20S proteasomes as well as the
degradation of antizyme-targeted ornithine decarboxylase–
OVA hybrid protein by purified 26S proteasomes (45) resulted
in the generation of the immunodominant OVA257-264
peptide, indicating that the steps upstream of 20S-mediated
proteolysis and substrate length are unlikely to influence spec-
ificity and frequency of cleavage site usage.
Proteasomes of mouse and of human origin cleave the
HBV model substrate identically (Table I), which, consid-
ering .90% homology between the subunits from the two
species, is not too surprising. These results are in line with a
recent study by Niedermann et al. (46) demonstrating that
the processing of polypeptides by proteasomes is conserved
in evolution. In contrast, our data seem inconsistent with
the recent work by Braud et al. (47), who showed that an
MHC class I HLA-A3–presented nonamer peptide derived
from the influenza nucleoprotein (NP) was generated in
human but not in mouse cells. However, the proteolytic
processes involved in the generation of the NP peptide
were not studied in depth, which will be needed to deter-
mine whether and how proteasome subunits contribute to
the processing defect in mouse cells. Still, although funda-
mental differences in cleavage specificities between protea-
somes of human and mouse origin seem unlikely, we can
not exclude the possibility that certain differences do exist
and are detected only when suitable specific substrates are
analyzed.
How does the synthesis of three additional catalytic pro-
teasome subunits contribute to the formation of MHC class
I ligands in IFN-g–induced cells? As discussed by Nandi et
al. (30), the expression of six different catalytic subunits
creates the theoretical possibility for 36 different protea-
some subpopulations. As these subpopulations are likely to
exhibit distinct cleavage properties, their presence could
lead to a diversification of cleavage site usage in Ag degra-
dation and thus broaden the repertoire of antigenic pep-
tides. This model, however, is opposed by recent findings
that LMP2 and MECL-1 and also, to a lesser extent, LMP7
incorporate interdependently into proteasomes (34, 37, 48).
Thus, less variety and the formation of homogenous im-
munoproteasomes is favored, suggesting that the immuno-
subunits fulfill a specific function. Based on our data, we
propose that both cleavage specificities and structural
changes imposed by immunosubunit incorporation lead to
an altered cleavage site usage by immunoproteasomes, broad-
ening the spectrum of peptides that is generated and avail-
able for association with MHC class I molecules. Such a
model is supported by the findings of Cardozo and Kohaski
(49), who showed that immunosubunit incorporation was
associated with an acceleration of proteasomal cleavages af-
ter branched chain residues (Leu, Ile, and Val) in lysozyme
substrate, leading to an enhanced generation of potential
MHC class I ligands. Recent results in our laboratory fur-
ther demonstrate that purified immunoproteasomes de-
grade the pp89 polypeptide faster than constitutive protea-
somes, with more dual cleavage products generated at early
time points of digestion (Kuckelkorn, U., T. Ruppert, and
P.-M. Kloetzel, unpublished observations), like observed
with the HBV 32-mer (Fig. 4). Thus, the immunosubunits
and the proteasome activator PA28 could mediate similar
effects, i.e., modification of the cleavage mechanism of the
20S proteasomes to enhance the formation of peptides via
coordinated double cleavage events (reference 11 and our
unpublished observations). Likely, both of these mecha-
nisms act together to enhance the antigenic peptide pro-
duction in IFN-g–stimulated cells.
LMP2, LMP7, and MECL-1 are constitutively highly ex-
pressed in many cells of lymphoid origin, probably including
APCs. Other cells do not express these subunits unless stimu-
lated by IFN-g. Thus, the set of antigenic peptides generated
by professional APCs to prime CTLs may differ from the set
of peptides produced by and presented on cells of nonlym-
phoid origin. This may have important biological conse-
quences. The work of Restifo et al. (50) and Seliger et al. (51)
indicated that the expression of the IFN-g–inducible protea-
some subunits influenced the antigenicity of tumor cells.
They found that the downregulation of LMP2 and LMP7 in
tumor cells was associated with enhanced immune escape.
Differences in induced and constitutive proteasome composi-
tion may affect the CTL-mediated immune defence against
intracellular pathogens. For example, while HBcAg141-151
is processed by immunoproteasomes only, hepatocytes
mostly contain constitutive proteasomes (reference 52 and
Seifert, U., A.J.A.M. Sijts, and P.-M. Kloetzel, unpublished
observations). Thus, HBcAg141-151 can be produced in511 Sijts et al.
HBV-infected hepatocytes during the acute phase of infec-
tion only in the presence of lymphokines that induce the
synthesis of LMP2, LMP7, and MECL-1. The peptide may
not be generated during chronic stages of infection, when
lymphokine levels have declined. Thus, the failure of hepa-
tocytes to generate certain viral peptides could potentially
contribute to the success of HBV to persist in chronically in-
fected patients. Indeed, an HBV-specific CTL response is
weak and only rarely detectable in the blood of patients with
chronic HBV infection, whereas it is strong and multispecific
in patients with acute hepatitis B (35). Another example is
provided by the finding that in absence of immunocompe-
tence, the lack of IFN-g precludes the efficient presentation
of antigens and CTL control in vivo (53). Further studies ad-
dressing the tissue distribution of distinct proteasome popula-
tions and their cleavage properties under in vivo conditions
will contribute to our understanding of CTL-mediated im-
munity and can perhaps shed light on the failure of immune
surveillance during chronic viral disease. These studies may
therefore provide a basis for the rational design of immuno-
therapeutic strategies.
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